<p>Panduranga Rao and Nagendra Hegde of Ella Foundation in India will develop and test for use in a vaccine a live single-cycle poliovirus that has been modified to eliminate the gene essential for replication. This highly disabled virus will be tested for its immunogenicity and its inability to re-emerge as vaccine-derived poliovirus (VDPV).</p>


Panduranga Rao and Nagendra Hegde of Ella Foundation in India will develop and test for use in a vaccine a live single-cycle poliovirus that has been modified to eliminate the gene essential for replication. This highly disabled virus will be tested for its immunogenicity and its inability to re-emerge as vaccine-derived poliovirus (VDPV).